CBN, or cannabinol, is a cannabinoid from the hemp plant that has hardly been in the spotlight so far. Unlike THC, it does not have an intoxicating effect, and it also differs significantly from CBD. Initial studies show that CBN could have interesting effects on well-being, especially in combination with other cannabinoids.
Despite this, CBN is on shaky legal ground in Switzerland. The reason: a blanket ban on synthetic cannabinoids from 2023, which unintentionally also affects CBN, even though it is considered safe internationally. Time for a closer look at a molecule that deserves more attention.
CBN is not a main component of young hemp plants. It only develops over time - when tetrahydrocannabinolic acid (THCA) breaks down under the influence of light and oxygen and converts into cannabinolic acid (CBNA). If this plant material is then heated, the acid splits off through decarboxylation - and CBN is formed.
CBN is chemically related to THC, but has a completely different effect profile. While THC binds strongly to CB1 receptors (especially in the brain) and provides psychoactive effects, CBN mainly binds to CB2 receptors - which are more responsible for the immune system and inflammation-related processes. This means that CBN is not intoxicating, but has potentially calming, anti-inflammatory properties
.
In 2023, a far-reaching ban on so-called new psychoactive substances was passed in Switzerland. The aim was to curb the spread of synthetic cannabinoids such as HHC. CBN also came under scrutiny - even though it has no psychoactive effect.
The problem: Naturally occurring CBN, which is extracted from the plant, was not clearly differentiated from synthetically produced CBN in the course of the ban. The extraction processes for CBN, CBD and CBG are very similar - both of which are now approved substances.
The result is a legal gray area: Synthetic CBN is clearly prohibited in Switzerland. For natural CBN, however, the situation is unclear - although the WHO does not classify it as dangerous or addictive and it does not fall under the UN drug control conventions.
The IG Hemp Switzerland is also calling for more differentiated regulation. In a recent position paper, it points out that the ban includes unprocessed, natural CBN - even though it is neither considered addictive nor internationally classified as a controlled substance. It calls for the regulation to be amended accordingly.
Although CBN has not yet been researched as intensively as CBD, there are indications of potential applications: for example for sleep problems, for inflammation inhibition or in regeneration. Particularly interesting: In combination with other cannabinoids, CBN appears to unfold its effect - a principle known as the entourage effect.
It is therefore not a panacea, but a promising building block in a differentiated therapeutic approach. And it is particularly helpful for medical professionals to be aware of such differences - in order to provide well-founded information and offer patients guidance.
A look at France makes it clear that differentiated regulations are possible: Although a ban on synthetic cannabinoids was introduced there - CBN was explicitly exempted.
Even at international level, there is no evidence that CBN poses a danger. The WHO has not recommended CBN for inclusion in the list of controlled substances, and from a legal perspective, there are good arguments for a clear distinction.
The blanket ban on CBN in Switzerland currently goes beyond what is necessary to protect the population - and at the same time makes research and medical development more difficult.
At Sainfort, we advocate a differentiated view of cannabinoids. After all, not every substance with a similar structure has the same effect - and not every innovation should be slowed down by blanket regulation.